Has Trump ’ s Case Affected Your Impression of COVID-19? Has Trump ’ s Case Affected Your Impression of COVID-19?

Just over a week after President Trump announced he had tested positive for SARS-CoV-2 infection, the White House doctor said the president was'no longer considered a transmission risk to others. 'Medscape Reader Polls
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

Related Links:

AbstractObjectivesWe investigate the effects of Ginger, compared to the usual therapeutic regimen on clinical manifestations and paraclinical features in patients with confirmed COVID-19 that are moderately ill.Trial designThis is a single center, randomized, double-blind, placebo-controlled clinical trial with parallel group design.ParticipantsInclusion criteria:1. Patients admitted to Severe Acute Respiratory Syndrome (SARS) Departments at Shahid Mohammadi Hospital, Bandar Abbas, Iran2. Age ≥18 years (weight ≥35 kg)3. Hospitalized ≤48 hours4. Confirmed SARS-CoV-2 diagnosis (Positive polymerase chain reaction (PC...
Source: Trials - Category: Research Source Type: clinical trials
In a report published Oct. 8 in the New England Journal of Medicine, researchers confirmed the benefits of remdesivir for treating people hospitalized for COVID-19. Remdesivir, an antiviral drug, has emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for treating anyone hospitalized for COVID-19. That authorization means that doctors can prescribe the intravenous (IV) drug for people who are infected with SARS-CoV-2 and have been hospitalized. While the drug was initially authorized only for those who needed supplemental oxygen or ventilators to breathe, an expanded EUA from the FDA in late ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
(NIH/National Institute of Allergy and Infectious Diseases) A clinical trial to test the safety, tolerability and efficacy of a combination treatment regimen for COVID-19 consisting of the antiviral remdesivir plus a highly concentrated solution of antibodies that neutralize SARS-CoV-2 has begun. The study is taking place in hospitalized adults with COVID-19 in the United States, Mexico and 16 other countries on five continents. NIAID is sponsoring and funding the Phase 3 trial, called Inpatient Treatment with Anti-Coronavirus Immunoglobulin, or ITAC.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Although antibodies to SARS-CoV-2 might wane over time, researchers suggest memory B cell immunity could remain and ramp up quickly to prevent severe re-infections.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
AbstractThe coronavirus disease (COVID-19) is caused by Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and presents with respiratory symptoms which can be life threatening in severe cases. At the start of the pandemic, allergy, asthma, and chronic obstructive pulmonary disease (COPD) were considered as risk factors for COVID-19 as they tend to exacerbate during respiratory viral infections. Recent literature has not shown that airway allergic diseases is a high-risk factor or that it increases the severity of COVID-19. This is due to a decrease in Angiotensin-converting enzyme 2 (ACE2) gene expression in the ...
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
CONCLUSION: Drilling and microdebrider use during endonasal surgery in a standard operating room is associated with a significant increase in airborne particle concentrations. Fortunately, this increase in aerosol concentration is localized to the area of the operating surgeon, with no detectable increase in aerosol particles at other OR positions. PMID: 33012174 [PubMed - as supplied by publisher]
Source: American Journal of Rhinology and Allergy - Category: ENT & OMF Authors: Tags: Am J Rhinol Allergy Source Type: research
A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults. A report published today in the New England Journal of Medicine describes the findings from the study, which was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured EMA Regulatory Affairs Source Type: news
The newly described severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is responsible for a pandemic (Corona virus-induced disease -19, COVID-19). It is now well established that certain comorbidities define high risk patients. They include hypertension, diabetes, and coronary artery disease. In contrast, the context with bronchial asthma is controversial and shows marked regional differences. Since asthma is the most prevalent chronic inflammatory lung disease worldwide and SARS-CoV-2 primarily affects the upper and lower airways leading to marked inflammation, the question arises about the possible clinical an...
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
We thank Zwaveling et  al1 for appreciating our review2 and for their insightful correspondence. They suggest that suppression of angiotensin-converting enzyme-2 (ACE-2) by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could impair the hydrolysis of des-Arg9-bradykinin and stimulate the bradykinin recepto r type 1 (BKB1) pathway to induce leakage of fluid into the lungs. In support of their hypothesis, they stated that loss of ACE-2 in an animal model aggravated acid-induced pulmonary edema, and these effects are alleviated by administration of recombinant human ACE-2.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Source Type: research
Jian et  al1 in a recent article refer to the immune reaction of the upper respiratory tract (URT) in patients infected by severe acute respiratory syndrome coronavirus (SARS-CoV)-2 (coronavirus disease 2019 [COVID-19] pandemic). The authors wonder about the consequences of inhaled corticosteroids (ICSs) o n immune reaction. We share the queries of Jian et al, from a practical point of view.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Correspondence Source Type: research
More News: Allergy | Allergy & Immunology | American Health | COVID-19 | Infectious Diseases | SARS | Trump | USA Health